View on GitHub

This release contains updates to the draft version of the database with FDA precision oncology approvals for Akeega. Additionally, the Organizations table was merged into the Agents table.

Database content updates

Added entries:

  • (FDA) BRCA2 oncogenic and pathogenic variants and sensitivity to niraparib and abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-sensitive prostate cancer.

Revised entries:

  • (FDA) BRCA1/2 oncogenic and pathogenic variants and sensitivity to niraparib and abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer was incorrectly listed as initially published in 2018 instead of 2023.

New features

  • The description written for each statement associated with an indication from the indications table will now populate the description field when dereferencing the database.
  • The Agents and Organizations table were merged to align with VA-Spec.